Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 20Triple Negative Breast Neoplasms 6Ovarian Neoplasms 3Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Endometrial Neoplasms 2Disease Progression 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Multiple Myeloma 1Lymphoma 1Lung Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer) 1Glioma 1Fallopian Tube Neoplasms 1Estrogen Receptor Positive Breast Cancer 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Fulvestrant 10Letrozole 4Alpelisib 4ribociclib 3palbociclib 3Paclitaxel 2NVP-BKM120 2volagidemab 1serabelisib 1sapanisertib 1olaparib 1liposomal doxorubicin 1gedatolisib 1exemestane 1dapagliflozin 1capivasertib 1abemaciclib 1Taxes 1Tamoxifen 1Secretin 1STX-478 1Metformin 1Lomustine 1Leuprolide 1Irinotecan 1Imlunestrant 1Goserelin 1Gemcitabine 1Drug Therapy 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × capivasertib × Breast × Clear all
NCT01226316 2025-06-29

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

AstraZeneca

Phase 1 Completed
285 enrolled
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡